How hard you are pushing the antihypertensives tells you how the pre-eclampsia is going

The edition in brief

Today's obstetric reading is dominated by expectant management of early pre-eclampsia. A retrospective cohort of 396 singleton pregnancies managed expectantly between 23 and 33 weeks found that each additional oral antihypertensive dose escalation was associated with an absolute 4.2 percentage point rise in composite maternal risk, with adjusted relative risks of 4.07 for three escalations and 5.20 for four or more against none. Neonatal outcomes did not differ. The treatment trajectory, in other words, behaves as a marker of how the disease is moving rather than as treatment that fixes it. A secondary analysis of two randomised trials from Cape Town makes the same argument from the urine: among 291 women managed expectantly from 26 to 32 weeks, median latency fell from 15.3 days below 3 g per 24 hours to 4.9 days at 5 g or more, and composite maternal complications rose from 8.8 percent to 27.9 percent across the same bands. Perinatal outcomes did not track proteinuria, and the sFlt-1/PlGF ratio performed similarly for maternal events. Away from the labour ward, a clinical toolkit sets out hormonal options for perimenopause, a stage with no dedicated guideline, where contraceptive need and cardiometabolic risk have to be weighed alongside symptoms. A Brazilian secondary analysis links better early-pregnancy diet quality with modestly higher birth weight and length and with infant length at six months. And an open-label trial of periprocedural music during intrauterine insemination missed its primary psychological endpoint flatly, while an unpowered secondary showed a higher clinical pregnancy rate — a result worth replicating, not acting on.